CMN-005 by CoImmune for Follicular Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Follicular Lymphoma.

Surrey research offers new hope for people suffering from immunodeficiencies

Several rare immune disorders are caused by mutations in the patient’s DNA. The University of Surrey and its collaborators found that targeting the mutated pathways

December 12, 2024

Avian flu’s leap to humans: Understanding risks and prevention strategies

Comprehensive report by the EFSA and ECDC delves into the factors that could prompt an avian influenza virus to evolve and potentially spark a pandemic,

April 10, 2024

Supervisory Board extends contracts with members of the Executive Board Mi-Young Miehler and Christoph Prußeit – Biotech Investments

EQS-News: Medios AG / Key word(s): Contract Medios AG: Supervisory Board extends contracts with members of the Executive Board Mi-Young Miehler and Christoph Prußeit 01.02.2024

February 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.